Osteosarcoma Research Portal logoOsteosarcoma Research Portal

Sources

All 201 links and DOIs cited in the videos, drug pages, portal entries, survival data, the Support from the USA page and the News page, collected automatically at build time.

  1. doi:10.1001/jamaoncol.2024.4381
    Used in: Drug: Lenvatinib (Lenvima); Level 2: FINAL_SCRIPTS_L2.md
  2. doi:10.1002/bit.260110607
    Used in: Drug: Doxorubicin
  3. doi:10.1002/cncr.34163
    Used in: Level 1: FINAL_SCRIPTS_v2.md
  4. doi:10.1016/j.annonc.2021.08.1995
    Used in: Drug: Mifamurtide (Mepact); Level 2: treatment_by_country.md
  5. doi:10.1016/j.ejca.2018.11.027
    Used in: Drug: Cisplatin; Drug: Doxorubicin; Drug: High-dose methotrexate; Level 1: FINAL_SCRIPTS_v2.md; Level 2: FINAL_SCRIPTS_L2.md
  6. doi:10.1016/S1470-2045(14)71136-2
    Used in: Drug: Sorafenib (Nexavar); Level 2: FINAL_SCRIPTS_L2.md
  7. doi:10.1016/S1470-2045(16)30096-1
    Used in: Drug: Zoledronic acid (Zometa); Level 2: treatment_by_country.md
  8. doi:10.1016/S1470-2045(16)30214-5
    Used in: Drug: Etoposide; Drug: Ifosfamide; Level 2: FINAL_SCRIPTS_L2.md
  9. doi:10.1016/S1470-2045(17)30624-1
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy; Level 2: FINAL_SCRIPTS_L2.md
  10. doi:10.1016/S1470-2045(18)30742-3
    Used in: Drug: Regorafenib (Stivarga); Level 2: FINAL_SCRIPTS_L2.md
  11. doi:10.1016/S1470-2045(19)30825-3
    Used in: Drug: Cabozantinib (Cabometyx); Level 2: FINAL_SCRIPTS_L2.md
  12. doi:10.1038/205698a0
    Used in: Drug: Cisplatin
  13. doi:10.1056/NEJM198606193142502
    Used in: Drug: High-dose methotrexate
  14. doi:10.1093/annonc/mdr151
    Used in: Drug: Sorafenib (Nexavar); Level 2: FINAL_SCRIPTS_L2.md
  15. doi:10.1136/bmjopen-2018-025877
    Used in: Level 2: treatment_by_country.md
  16. doi:10.1136/jitc-2020-000798
    Used in: Drug: Apatinib (rivoceranib)
  17. doi:10.1158/1078-0432.CCR-24-2885
    Used in: Drug: Denosumab (Xgeva)
  18. doi:10.1158/1078-0432.CCR-25-3282
    Used in: Level 2: treatment_by_country.md
  19. doi:10.1186/s13569-016-0047-1
    Used in: Level 2: treatment_by_country.md
  20. doi:10.1200/JCO.18.02374
    Used in: Drug: Regorafenib (Stivarga); Level 2: FINAL_SCRIPTS_L2.md
  21. doi:10.1200/JCO.2008.14.0095
    Used in: Drug: Mifamurtide (Mepact); Level 2: FINAL_SCRIPTS_L2.md
  22. doi:10.1200/JCO.2014.58.0225
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy; Level 2: FINAL_SCRIPTS_L2.md
  23. doi:10.1634/theoncologist.2018-0542
    Used in: Drug: Apatinib (rivoceranib); Level 2: FINAL_SCRIPTS_L2.md
  24. http://static.cninfo.com.cn/finalpage/2020-11-03/1208675554.PDF
    Used in: Drug: Cabozantinib (Cabometyx)
  25. https://actaorthop.org/actao/article/view/29176
    Used in: Survival data
  26. https://amgen.com.cn/en/media/amgen-denosumab.html
    Used in: Drug: Denosumab (Xgeva)
  27. https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125320
    Used in: Drug: Denosumab (Xgeva)
  28. https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125514
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy
  29. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA011719
    Used in: Drug: High-dose methotrexate
  30. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018057
    Used in: Drug: Cisplatin
  31. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018768
    Used in: Drug: Etoposide
  32. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA019763
    Used in: Drug: Ifosfamide
  33. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA021223
    Used in: Drug: Zoledronic acid (Zometa)
  34. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA021923
    Used in: Drug: Sorafenib (Nexavar)
  35. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA050467
    Used in: Drug: Doxorubicin
  36. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA203085
    Used in: Drug: Regorafenib (Stivarga)
  37. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA203756
    Used in: Drug: Cabozantinib (Cabometyx)
  38. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206947
    Used in: Drug: Lenvatinib (Lenvima)
  39. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA208692
    Used in: Drug: Cabozantinib (Cabometyx)
  40. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212937
    Used in: Drug: Cisplatin
  41. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22CABOMETYX%22
    Used in: Drug: Cabozantinib (Cabometyx)
  42. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ETOPOPHOS%22
    Used in: Drug: Etoposide
  43. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22NEXAVAR%22
    Used in: Drug: Sorafenib (Nexavar)
  44. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22PEDMARK%22
    Used in: Drug: Cisplatin
  45. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22Stivarga%22
    Used in: Drug: Regorafenib (Stivarga)
  46. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22XGEVA%22
    Used in: Drug: Denosumab (Xgeva)
  47. https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dexrazoxane%22
    Used in: Drug: Doxorubicin
  48. https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22glucarpidase%22
    Used in: Drug: High-dose methotrexate
  49. https://assets.hpra.ie/products/Human/15731/Licence_PA2299-028-001_11092023124600.pdf
    Used in: Drug: Ifosfamide
  50. https://assets.hpra.ie/products/Human/22078/Licence_PA0822-199-001_09112026181407.pdf
    Used in: Drug: Cisplatin
  51. https://assets.hpra.ie/products/Human/22092/Licence_PA0822-206-007_11092026121412.pdf
    Used in: Drug: High-dose methotrexate
  52. https://assets.hpra.ie/products/Human/27561/Licence_PA2315-083-001_20022024123027.pdf
    Used in: Drug: Doxorubicin
  53. https://assets.hpra.ie/products/Human/27660/Licence_PA2315-201-001_13032024133422.pdf
    Used in: Drug: Etoposide
  54. https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-357
    Used in: Survival data
  55. https://cjournal.hep.com.cn/0253-3626/CN/10.13406/j.cnki.cyxb.004023
    Used in: Level 2: treatment_by_country.md
  56. https://clinicaltrials.gov/study/NCT00470223
    Used in: Portal: Zoledronic acid with chemotherapy (OS2006, NCT00470223)
  57. https://clinicaltrials.gov/study/NCT02470091
    Used in: Portal: Denosumab (COG AOST1321, NCT02470091)
  58. https://clinicaltrials.gov/study/NCT03449108
    Used in: Portal: LN-145 TIL therapy (NCT03449108)
  59. https://clinicaltrials.gov/study/NCT03598595
    Used in: Portal: Gemcitabine and docetaxel with hydroxychloroquine (NCT03598595)
  60. https://clinicaltrials.gov/study/NCT03628209
    Used in: Portal: Nivolumab with or without azacitidine (NCT03628209)
  61. https://clinicaltrials.gov/study/NCT03643133
    Used in: Portal: Mifamurtide added to post-operative chemotherapy in high-risk osteosarcoma (SARCOME13, NCT03643133)
  62. https://clinicaltrials.gov/study/NCT03900793
    Used in: Portal: Losartan with sunitinib (NCT03900793)
  63. https://clinicaltrials.gov/study/NCT04417062
    Used in: Portal: Olaparib with ceralasertib in recurrent osteosarcoma (NCT04417062)
  64. https://clinicaltrials.gov/study/NCT04616560
    Used in: Portal: Trastuzumab deruxtecan (DS-8201a) in recurrent osteosarcoma (NCT04616560)
  65. https://clinicaltrials.gov/study/NCT04698785
    Used in: Portal: Regorafenib maintenance (REGOMAIN, NCT04698785)
  66. https://clinicaltrials.gov/study/NCT04758000
    Used in: Portal: Metformin maintenance in high-risk bone sarcoma (NCT04758000)
  67. https://clinicaltrials.gov/study/NCT04974008
    Used in: Portal: OST31-164 maintenance after lung relapse
  68. https://clinicaltrials.gov/study/NCT05019703
    Used in: Portal: Atezolizumab with cabozantinib (TACOS)
  69. https://clinicaltrials.gov/study/NCT05395741
    Used in: Portal: Regorafenib (Regbone NCT05395741)
  70. https://clinicaltrials.gov/study/NCT05492682
    Used in: Portal: PeptiCRAd-1 with pembrolizumab (NCT05492682)
  71. https://clinicaltrials.gov/study/NCT05590572
    Used in: Portal: Sulfatinib with ifosfamide and etoposide (NCT05590572)
  72. https://clinicaltrials.gov/study/NCT05660408
    Used in: Portal: RNA lipid particle vaccine (RNA PRIME / NCT05660408)
  73. https://clinicaltrials.gov/study/NCT05691478
    Used in: Level 2: FINAL_SCRIPTS_L2.md
  74. https://clinicaltrials.gov/study/NCT05726383
    Used in: Portal: Mistletoe extract Iscador P (NCT05726383)
  75. https://clinicaltrials.gov/study/NCT05830123
    Used in: Portal: HS-20093 (B7-H3 antibody-drug conjugate) ARTEMIS-002
  76. https://clinicaltrials.gov/study/NCT06474676
    Used in: Portal: attIL12-TIL (NCT06474676)
  77. https://clinicaltrials.gov/study/NCT06714383
    Used in: Portal: Trilaciclib with neoadjuvant chemotherapy (NCT06714383)
  78. https://clinicaltrials.gov/study/NCT06892678
    Used in: Portal: DFMO (eflornithine) maintenance
  79. https://clinicaltrials.gov/study/NCT07142863
    Used in: Portal: Envafolimab with neoadjuvant chemotherapy (NCT07142863)
  80. https://clinicaltrials.gov/study/NCT07144254
    Used in: Portal: Tegavivint with gemcitabine
  81. https://clinicaltrials.gov/study/NCT07193550
    Used in: Portal: Zanzalintinib (XL092) ZAMBONE
  82. https://clinicaltrials.gov/study/NCT07357519
    Used in: Portal: LNTH-2403 (LRRC15-targeted lutetium-177 antibody, Lu-TARGO, NCT07357519)
  83. https://clinicaltrials.gov/study/NCT07428993
    Used in: Portal: B7-H3 CAR T cells (SJCARB7H3-41BBL) after MAP chemotherapy
  84. https://clinicaltrials.gov/study/NCT07477457
    Used in: Portal: Gefitinib, trametinib, disulfiram and sunitinib with chemotherapy (OstEvo, NCT07477457)
  85. https://clinicaltrials.gov/study/NCT07479732
    Used in: Portal: Apatinib with liposomal irinotecan (NCT07479732)
  86. https://clinicaltrials.gov/study/NCT07619950
    Used in: Portal: Everolimus with lenvatinib (NCT07619950)
  87. https://clinicaltrials.gov/study/NCT07725380
    Used in: Portal: Domatinostat with sirolimus
  88. https://clinicaltrials.gov/study/NCT07787429
    Used in: Portal: Mifamurtide versus sorafenib (Dragonfly, NCT07787429)
  89. https://clinicaltrials.gov/study/NCT07871864
    Used in: Level 2: FINAL_SCRIPTS_L2.md; Portal: FOSTER platform trial (cabozantinib arm)
  90. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e30eaef-5a09-4104-8a11-c32933eadeab
    Used in: Drug: High-dose methotrexate
  91. https://doi.org/10.1200/jco.18.02374
    Used in: Portal: Regorafenib (SARC024 trial, osteosarcoma cohort)
  92. https://drugs.dxy.cn/drug/0JhFqeRKboisKq8Gf6JQVA==
    Used in: Drug: Apatinib (rivoceranib); Level 2: FINAL_SCRIPTS_L2.md
  93. https://drugs.dxy.cn/pc/clinicalDecision/TJCplsplswFbnAoY9Pgxm4GGQHw==?ky=osa
    Used in: Level 2: treatment_by_country.md
  94. https://elevartx.com/2018/01/02/lskb-announces-official-nonproprietary-naming-of-apatinib-yn968d1-rivoceranib/
    Used in: Drug: Apatinib (rivoceranib)
  95. https://elevartx.com/2026/07/10/elevar-crl-july-2/
    Used in: Drug: Apatinib (rivoceranib)
  96. https://europepmc.org/article/med/31246277
    Used in: Level 2: treatment_by_country.md
  97. https://europepmc.org/article/PMC/PMC2528159
    Used in: Survival data
  98. https://europepmc.org/article/PMC/PMC5984426
    Used in: Survival data
  99. https://europepmc.org/article/PMC/PMC7469730
    Used in: Survival data
  100. https://healx.ai/healx-announces-first-patient-dosed-in-phase-1-2-trial-to-evaluate-the-effect-of-hlx-4310-on-metastatic-recurrence-and-progression-in-sarcomas-with-a-focus-on-osteosarcoma/
    Used in: News: First patient dosed in Healx trial of HLX-4310, with a focus on osteosarcoma
  101. https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-partner-takeda-receives-approval-japan
    Used in: Drug: Cabozantinib (Cabometyx)
  102. https://ir.ostherapies.com/news-events/press-releases/detail/128/os-therapies-achieves-incremental-alignment-with-fda-and
    Used in: News: OS Therapies reports further FDA alignment and a UK Project Orbis invitation for OST-HER2
  103. https://ir.ostherapies.com/news-events/press-releases/detail/56/os-therapies-completes-acquisition-of-advaxis
    Used in: News: OS Therapies completes purchase of Ayala's listeria immunotherapy assets
  104. https://ir.ostherapies.com/news-events/press-releases/detail/64/os-therapies-partners-with-eversana-for-the-u-s
    Used in: News: OS Therapies partners with EVERSANA to prepare a US launch of OST-HER2
  105. https://netsarc.sarcomabcb.org/
    Used in: Level 2: treatment_by_country.md
  106. https://njguloulib.yuntsg.com/ueditor/jsp/upload/file/20210608/1623115700638048095.pdf
    Used in: Level 2: treatment_by_country.md
  107. https://osinst.org/
    Used in: Support from the USA
  108. https://osinst.org/blog/2025-grant-recipients/
    Used in: News: Osteosarcoma Institute awards more than $1.5 million for four research projects
  109. https://osinst.org/blog/andreas-story/
    Used in: News: Andrea Helfer on life more than 30 years after childhood osteosarcoma
  110. https://osinst.org/blog/anthony-olivero-story/
    Used in: News: Anthony Olivero is cancer-free two years after a five-year outlook as a teenager
  111. https://osinst.org/donate/
    Used in: Support from the USA
  112. https://osinst.org/partnering-for-progress/
    Used in: Support from the USA
  113. https://osinst.org/researchers/
    Used in: Support from the USA
  114. https://pdf.marketpublishers.com/shcri/investigation-report-on-chinese-sorafenib-market-2018-2022.pdf
    Used in: Drug: Sorafenib (Nexavar)
  115. https://pharm.ncmi.cn/zysjk/ypjkyp/202312/t20231205_399737.html
    Used in: Drug: Zoledronic acid (Zometa)
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC11343645/
    Used in: Drug: Doxorubicin; Level 2: FINAL_SCRIPTS_L2.md
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/
    Used in: Drug: Cisplatin; Drug: Doxorubicin; Drug: Etoposide; Drug: High-dose methotrexate; Drug: Ifosfamide; Drug: Lenvatinib (Lenvima); Drug: Regorafenib (Stivarga); Level 2: FINAL_SCRIPTS_L2.md; Level 2: treatment_by_country.md
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC2813207/
    Used in: Survival data
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC4414626/
    Used in: Survival data
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC5834019/
    Used in: Level 2: treatment_by_country.md
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC6162271/
    Used in: Level 2: FINAL_SCRIPTS_L2.md
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC6506906/
    Used in: Survival data
  123. https://pubmed.ncbi.nlm.nih.gov/11821461/
    Used in: Survival data
  124. https://pubmed.ncbi.nlm.nih.gov/21527590/
    Used in: Portal: Sorafenib (Italian Sarcoma Group phase 2)
  125. https://pubmed.ncbi.nlm.nih.gov/21913189/
    Used in: Survival data
  126. https://pubmed.ncbi.nlm.nih.gov/25498219/
    Used in: Portal: Sorafenib with everolimus (Italian Sarcoma Group, NCT01804374)
  127. https://pubmed.ncbi.nlm.nih.gov/26033801/
    Used in: Portal: Pegylated interferon alfa-2b maintenance (EURAMOS-1 good responders)
  128. https://pubmed.ncbi.nlm.nih.gov/27569442/
    Used in: Portal: Cisplatin (MAP chemotherapy); Portal: Doxorubicin (MAP chemotherapy); Portal: High-dose methotrexate (MAP chemotherapy); Portal: Ifosfamide with etoposide (EURAMOS-1 MAPIE)
  129. https://pubmed.ncbi.nlm.nih.gov/28833209/
    Used in: Survival data
  130. https://pubmed.ncbi.nlm.nih.gov/28988646/
    Used in: Portal: Pembrolizumab (SARC028)
  131. https://pubmed.ncbi.nlm.nih.gov/30477937/
    Used in: Portal: Regorafenib (REGOBONE trial, NCT02389244)
  132. https://pubmed.ncbi.nlm.nih.gov/31081028/
    Used in: Level 2: treatment_by_country.md
  133. https://pubmed.ncbi.nlm.nih.gov/31586757/
    Used in: Portal: Glembatumumab vedotin (NCT02487979)
  134. https://pubmed.ncbi.nlm.nih.gov/32078813/
    Used in: Portal: Cabozantinib (CABONE trial)
  135. https://pubmed.ncbi.nlm.nih.gov/35192571/
    Used in: Survival data
  136. https://pubmed.ncbi.nlm.nih.gov/3520317/
    Used in: Survival data
  137. https://pubmed.ncbi.nlm.nih.gov/39418029/
    Used in: Portal: Lenvatinib with ifosfamide and etoposide (ITCC-050 and OLIE)
  138. https://pubmed.ncbi.nlm.nih.gov/40455577/
    Used in: Survival data
  139. https://pubmed.ncbi.nlm.nih.gov/5225072/
    Used in: Survival data
  140. https://sarcoma.org.uk/research/reactivating-the-immune-system-to-tackle-osteosarcoma-that-has-spread-to-the-lungs/
    Used in: Portal: Tin mesoporphyrin (SnMP) for lung metastases (Sarcoma UK funded)
  141. https://sotio.com/news-publications/news/sotio-receives-u-s-fda-orphan-drug-designation-for-sot106-a-potential-best-in-class-adc-for-sarcoma
    Used in: News: US FDA grants orphan drug designation to SOT106 for osteosarcoma
  142. https://web.archive.org/web/20190423133424/https:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy
  143. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=143401
    Used in: Drug: Mifamurtide (Mepact); Level 2: FINAL_SCRIPTS_L2.md; Level 2: treatment_by_country.md
  144. https://www.bayer.com/media/en-us/bayer-receives-approval-in-china-for-stivargar-regorafenib-for-the-second-line-systemic-treatment-of-liver-cancer/
    Used in: Drug: Regorafenib (Stivarga)
  145. https://www.bbc.com/news/articles/cjrng9nxjd3o
    Used in: News: Family of Glasgow DJ Niamh Jobson launch an osteosarcoma research fund
  146. https://www.bcrt.org.uk/news/2025/december/introducing-our-first-ever-youth-ambassador
    Used in: News: Annabel Kiki becomes the Bone Cancer Research Trust's first Youth Ambassador
  147. https://www.bcrt.org.uk/news/2026/01/exploring-new-ways-to-help-the-immune-system-fight-osteosarcoma
    Used in: News: Bone Cancer Research Trust funds work to help the immune system fight osteosarcoma
  148. https://www.bcrt.org.uk/research/completed-research-projects/iconic
    Used in: Portal: ICONIC: Improving Outcomes through Collaboration in Osteosarcoma (registry and observational study)
  149. https://www.bcrt.org.uk/research/current-research-projects/advancing-iconic-(%E2%80%98ad-iconic%E2%80%99)
    Used in: Portal: Ad-ICONIC: Advancing the ICONIC trial
  150. https://www.bcrt.org.uk/research/current-research-projects/kinder-drugs-to-treat-osteosarcoma
    Used in: Portal: Kinder drugs: tumour-targeted methotrexate prodrugs
  151. https://www.bcrt.org.uk/research/current-research-projects/mimicking-the-journey-through-the-bloodstream-exploring-how-osteosarcoma-cells-spread-and-survive-elsewhere-in-the-body
    Used in: Portal: Mimicking the journey through the bloodstream: circulating osteosarcoma cells
  152. https://www.bcrt.org.uk/research/current-research-projects/searching-for-new-drugs-to-treat-osteosarcoma
    Used in: Portal: Searching for new drugs to treat osteosarcoma (preclinical validation of novel compounds)
  153. https://www.bcrt.org.uk/research/current-research-projects/stopping-the-alpha-a-potential-new-treatment-approach-for-osteosarcoma
    Used in: Portal: Stopping the alpha: IKKα inhibitors for osteosarcoma
  154. https://www.bcrt.org.uk/research/current-research-projects/towards-precision-medicine-in-osteosarcoma
    Used in: Portal: PARP inhibitors for RB1-mutated osteosarcoma (Bone Cancer Research Trust funded)
  155. https://www.bjcancer.org.cn/Html/News/Articles/8768.html
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy
  156. https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate-sodium
    Used in: Drug: High-dose methotrexate; Level 2: FINAL_SCRIPTS_L2.md
  157. https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq
    Used in: Level 2: FINAL_SCRIPTS_L2.md; Level 2: treatment_by_country.md
  158. https://www.cancer.org/cancer/types/osteosarcoma/detection-diagnosis-staging/survival-rates.html
    Used in: Survival data
  159. https://www.cancerresearchuk.org/about-cancer/bone-cancer/survival
    Used in: Survival data
  160. https://www.cancerresearchuk.org/about-cancer/bone-cancer/treatment/chemotherapy
    Used in: Level 2: FINAL_SCRIPTS_L2.md
  161. https://www.cancertherapyadvisor.com/ddi/bone-cancer-treatment-pharmacologic-management/
    Used in: Drug: Cabozantinib (Cabometyx); Drug: Ifosfamide; Drug: Regorafenib (Stivarga); Drug: Sorafenib (Nexavar); Level 2: treatment_by_country.md
  162. https://www.eisai.com/news/2018/news201818.html
    Used in: Drug: Lenvatinib (Lenvima)
  163. https://www.eisai.com/news/2018/news201877.html
    Used in: Drug: Lenvatinib (Lenvima)
  164. https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf
    Used in: Level 2: treatment_by_country.md
  165. https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx
    Used in: Drug: Cabozantinib (Cabometyx); Drug: Denosumab (Xgeva); Drug: Lenvatinib (Lenvima); Drug: Mifamurtide (Mepact); Drug: Pembrolizumab (Keytruda) and immunotherapy; Drug: Regorafenib (Stivarga); Drug: Sorafenib (Nexavar); Drug: Zoledronic acid (Zometa)
  166. https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima
    Used in: Drug: Lenvatinib (Lenvima)
  167. https://www.ema.europa.eu/en/medicines/human/EPAR/mepact
    Used in: Drug: Mifamurtide (Mepact); Portal: Mifamurtide (Mepact)
  168. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3189
    Used in: News: EMA grants orphan designations to sirolimus and domatinostat for osteosarcoma
  169. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3190
    Used in: News: EMA grants orphan designations to sirolimus and domatinostat for osteosarcoma
  170. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy
  171. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy
  172. https://www.hengrui.com/en/media/detail-423.html
    Used in: Drug: Apatinib (rivoceranib)
  173. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/memos-a-eurosarc-study-of-mifamurtide-in-advanced-osteosarcoma/
    Used in: Portal: Mifamurtide in advanced osteosarcoma (MEMOS, ISRCTN82138287)
  174. https://www.iarc.who.int/reference/bone-tumours-in-european-children-and-adolescents-1978-1997-report-from-the-automated-childhood-cancer-information-system-project/
    Used in: Survival data
  175. https://www.indianmed.cn/drug-news/t2nz0hzctd4y.html
    Used in: Drug: Cabozantinib (Cabometyx)
  176. https://www.linchuangsy.com/Newsqa/Show/14269.html
    Used in: Drug: Cabozantinib (Cabometyx)
  177. https://www.medicines.org.uk/emc/product/10514/smpc
    Used in: Drug: Etoposide
  178. https://www.medicines.org.uk/emc/product/1834/smpc
    Used in: Drug: Ifosfamide
  179. https://www.medicines.org.uk/emc/product/210/smpc
    Used in: Drug: Zoledronic acid (Zometa)
  180. https://www.medicines.org.uk/emc/product/2498/smpc
    Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy
  181. https://www.medicines.org.uk/emc/product/3788/smpc
    Used in: Drug: Cisplatin
  182. https://www.medicines.org.uk/emc/product/7205/smpc
    Used in: Drug: Zoledronic acid (Zometa)
  183. https://www.medicines.org.uk/emc/product/8443/smpc
    Used in: Drug: Doxorubicin
  184. https://www.medicines.org.uk/emc/product/8504/smpc
    Used in: Drug: High-dose methotrexate
  185. https://www.nature.com/articles/s41416-024-02868-4
    Used in: Level 2: treatment_by_country.md
  186. https://www.nice.org.uk/guidance/ta235/chapter/1-Guidance
    Used in: Level 2: FINAL_SCRIPTS_L2.md
  187. https://www.nice.org.uk/guidance/ta235/chapter/1-Recommendations
    Used in: Level 2: treatment_by_country.md
  188. https://www.pnas.org/doi/10.1073/pnas.1419260111
    Used in: Level 2: FINAL_SCRIPTS_L2.md
  189. https://www.roswellpark.org/newsroom/202605-fl118-granted-fda-rare-pediatric-disease-designation-orphan-drug-designation
    Used in: News: FDA grants rare paediatric and orphan designations to FL118 for osteosarcoma
  190. https://www.sec.gov/Archives/edgar/data/822206/000110465909040297/a09-16803_2ex99d2.htm
    Used in: Drug: Mifamurtide (Mepact)
  191. https://www.sohu.com/a/1076774583_122732456
    Used in: Drug: Cabozantinib (Cabometyx)
  192. https://www.targetedonc.com/view/rivoceranib-plus-camrelizumab-resubmitted-to-fda-in-frontline-hcc
    Used in: Drug: Apatinib (rivoceranib)
  193. https://www.unc.edu/posts/2026/02/04/after-cancer-battle-camden-bailey-leaves-lasting-carolina-legacy/
    Used in: News: UNC-Chapel Hill remembers Camden Bailey, who founded a fund for osteosarcoma research
  194. https://www.yaodey.com/drug/state_60.html
    Used in: Drug: Cabozantinib (Cabometyx)
  195. https://www.yaodey.com/news/28242.html
    Used in: Level 2: FINAL_SCRIPTS_L2.md
  196. https://www.yaopinnet.com/H/H13/H20040813.htm
    Used in: Drug: Cisplatin
  197. https://www.yaopinnet.com/h/h18/H20041318.htm
    Used in: Drug: Doxorubicin
  198. https://www.yaopinnet.com/H/H45/H20263245.htm
    Used in: Drug: Etoposide
  199. https://www.yaopinnet.com/h/h57/H20183157.htm
    Used in: Drug: Zoledronic acid (Zometa)
  200. https://www.yaopinnet.com/h/h92/H20054692.htm
    Used in: Drug: High-dose methotrexate
  201. https://www.yaozs.com/z24590/
    Used in: Drug: Ifosfamide